glp-1 weight loss research with medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans GLP-1 Appetite Remains High. But

This data is invaluable for your first follow-up appointment

The DPP-4 inhibitors prolong the action of endogenous incretins, enhancing the first-phase insulin response

[5] [2] Patients starting GLP-1 therapy should be aware of: Potential mood changes during the adjustment period, particularly if experiencing significant gastrointestinal side effects The importance of continuing existing mental health treatments unless advised otherwise by their healthcare team Realistic expectations regarding weight loss and metabolic improvements, as unrealistic goals can lead to disappointment Healthcare professionals prescribing GLP-1 agonists should: Screen for depression and anxiety at baseline and during follow-up appointments Monitor for mood changes , particularly in patients with pre-existing mental health conditions Ensure coordinated care between diabetes/obesity services and mental health teams when appropriate It is essential to recognise that GLP-1 agonists are not a substitute for evidence-based depression treatments, including psychological therapies and antidepressant medications when indicated

MTA makes no claim that this Site is appropriate for access or use outside the United States